undamentalytics Newsletter
Sign in

Amylyx Pharmaceuticals, Inc. balance sheet

At the end of fiscal 2025, Amylyx Pharmaceuticals, Inc. had total assets of $333m, total liabilities of $27.4m and shareholders' equity of $305m. It held $227m in cash against $0 of debt: net cash of $227m.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025
Cash and equivalents506317077227
Receivables—154000
Inventory—1038——
Total current assets105382465189324
Total assets106391517194333
Accounts payable462234
Total current liabilities1747822823
Total debt00000
Total liabilities1751842927
Shareholders' equity−151341433165305
Non-controlling interests and other (assets − liabilities − equity)239————
Net debt (negative = net cash)−50−63−170−77−227
Shares outstanding7m67m68m69m110m

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Amylyx Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Amylyx Pharmaceuticals, Inc.